Key clinical point: Three fibrinogen biomarkers can provide useful information about disease endotypes and mortality risk in chronic obstructive pulmonary disease (COPD).
Major finding: The biomarkers X–FIB and fibrinogen were predictive of 2-year morality (adjusted hazard ratios of 1.48; P < 0.0001; and 1.59 per SD, n = 983, 95% CI, 1.29–1.96; P = .0003, respectively). X–FIB (P < .001), fibrinogen (P < .0001) and PRO-FIB (P < .05) were much higher in symptomatic vs. asymptomatic COPD.
Study details: Analysis of subpopulation of subjects from observational, longitudinal study: 983 patients with COPD, 205 smoking controls, and 98 nonsmoking controls.
Disclosures: GlaxoSmithKline, the Danish Agency for Science, Technology and Innovation, and the Danish Research Foundation funded the study. Seven study authors are employed by Nordic Bioscience, Biomarkers and Research, and some authors report various other disclosures.
Manon-Jensen T et al. Respir Med. 2019(160):105814.